ENTITY
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (GNP IN)

183
Analysis
Health Care • India
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company that develops, manufactures, and markets branded and generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on therapeutic areas including respiratory, dermatology, and oncology, with products such as Ryaltris, Winlevi, and Candid. It was founded in 1977 and is headquartered in Mumbai, India.
more
•30 Jun 2020 14:56

Asia HY Trade Recommendations - June 2020 - Lucror Analytics

The Asia HY Trade Recommendations report for the month of June includes a summary of our recommendations. The report also features relative-value...

Logo
510 Views
Share
bullish•Softbank Group
•29 Jun 2020 08:57

Morning Views Asia: Glenmark Pharmaceuticals, Softbank Group

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region,...

Logo
364 Views
Share
bullish•Jubilant Pharma Ltd
•26 Jun 2020 10:43

Jubilant Pharma: Good Drugs, Fully-Valued Bonds

We initiate our coverage of Jubilant Pharma Ltd (1164252D IN) (JPL) which is ranked top 2-3 global pharmaceutical company in the...

Logo
576 Views
Share
bullish•Hilong Holding
•23 Jun 2020 08:52

Morning Views Asia: Fosun International, Glenmark Pharmaceuticals, Modernland Realty, Softbank Group

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region,...

Logo
447 Views
Share
•21 Jun 2020 13:15

Glenmark Pharma: Approval for Covid-19 Oral Drug

In Unlock 1 Ill-Effects: Boon for the Consumer Discretionary? we highlighted the current covid 19 scenario where there is not a single trace of...

Logo
449 Views
Share
x